Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Tonix Pharmaceuticals Holding Corp maintains a gross margin of 58.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1005.08%, while the net margin is -972.95%. These profitability ratios, combined with a Return on Equity (ROE) of -64.99%, provide a clear picture of how effectively TNXP converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TNXP competes directly with industry leaders such as CHRS and SLGL. With a market capitalization of $192.84M, it holds a significant position in the sector. When comparing efficiency, TNXP's gross margin of 58.45% stands against CHRS's 67.84% and SLGL's 100.00%. Such benchmarking helps identify whether Tonix Pharmaceuticals Holding Corp is trading at a premium or discount relative to its financial performance.
